Druggio Logo

Druggio

Type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia due to insulin resistance of peripheral tissues (skeletal muscle, liver, adipose tissue) and insufficient compensatory insulin secretion by pancreatic beta cells. Both insulin resistance and beta cell dysfunction are thought to result from the complex interplay of many different pathways under the combined control of environmental and genetic factors. It is accepted that T2DM results from population aging and adverse environmental factors of the modern world which favor the development of obesity.

Drugs that treat Type 2 diabetes mellitus

Twymeeg

Approval date

2021/6/23

Ozempic

Made by

Novo Nordisk

Approval date

2018/3/23

Marizev

Made by

MSD

Approval date

2015/9/28

Trulicity

Made by

Eli Lilly

Approval date

2015/7/3

Zafatek

Made by

Takeda

Approval date

2015/3/26

Jardiance

Approval date

2014/12/26

Canaglu

Approval date

2014/7/4

Lusefi

Approval date

2014/3/24

Deberza, Apleway

Made by

KowaSanofi

Approval date

2014/3/24

Forxiga

Approval date

2014/3/24

Suglat

Approval date

2014/1/17

Lyxumia

Made by

Sanofi

Approval date

2013/6/28

Onglyza

Approval date

2013/3/25

Suiny, Beskoa

Approval date

2012/9/28

Tenelia

Approval date

2012/6/29

Trazenta

Approval date

2011/7/1

Surepost

Approval date

2011/1/21

Byetta

Made by

Eli Lilly

Approval date

2010/10/27

Nesina

Made by

Takeda

Approval date

2010/4/16

Equa

Made by

Novartis

Approval date

2010/1/20

Victoza

Made by

Novo Nordisk

Approval date

2010/1/20

Januvia

Made by

MSD

Approval date

2009/10/16

Apidra

Made by

Sanofi

Approval date

2009/4/22

Seibule

Approval date

2005/10/11

Glufast

Approval date

2004/1/29